Skip to main content
OpenTrials
Completed

NCT Number: NCT02992951

DACC in the REduction of Surgical Site INfection

Surgical site infection is an infection at a place in the body where surgery has taken place, and has been reported in around 5% of people undergoing an operation. In vascular surgery, infection rates are as high as 30%. Methods to reduce this rate of infection should be investigated thoroughly for their effectiveness and cost-effectiveness.

The investigators aim to conduct a research trial examining one such method. Leukomed Sorbact is a wound dressing coated with a chemical (DACC) derived from spider-silk that interacts with, and binds bacteria, causing them to be mechanically removed from a wound when the dressing is changed. The trial aims to compare the effectiveness of this dressing to a standard, non-coated dressing, in the reduction of surgical site infection.

718 patients from a number of centres across the UK will be recruited to this study. Adult patients who are having a vascular surgery operation will be approached for entry into the trial. The trial will be explained to them, as well as an explanation that participation is voluntary and their operation or other aspects of their care will not be impacted in any way should participants not wish to participate.

Participants will be randomised by computer into one of two groups - one group whose wounds are dressed with Leukomed Sorbact, and the other whose wounds are dressed with a standard dressing. Patients will be followed up at 30 days post-operatively. At the follow up, their wounds will be inspected for infection, and participants will be asked to complete short questionnaires measuring quality of life. Quality of life will also be assessed at 3 months post surgery.

The trial will aim to answer a number of questions, with the primary question being does a DACC coated dressing applied after an operation reduce the risk of an infection at the surgery site? It will also ask whether this treatment is cost-effective and whether it promotes satisfactory healing and evaluate the overall carbon footprint impact of each intervention.

Studies Within a Trial will be conducted to validate a remote diagnostic measure for detecting surgical site infection using wound images and the Bluebelle Wound Healing Questionnaire, evaluate feasibility of novel hair removal methods such as epilation and waxing, carbon footprint modelling within randomised controlled trials.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Academic Vascular Surgery Unit, Vascular Laboratory, Alderson House, Hull Royal Infirmary

Hull, East Riding of Yorkshire, HU3 2JZ, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

In order to be eligible for inclusion in the study the participants must meet the following criteria:

  • Adults ≥18 yrs undergoing clean or clean-contaminated lower limb vascular surgery, with wounds closed by primary intention.
  • Able to understand the Patient Information Sheet and supplementary materials and capable and willing to give informed consent and follow the protocol requirements (including attending all follow-up visits and completing written questionnaires).

Exclusion criteria

Patients will not be included in the study if they meet any of the following exclusion criteria:

  • Patients on antibiotics for other conditions at the time of surgery or in the follow up period.
  • Patients undergoing any procedure that does not include lower limb incisions.
  • Allergies to any component of either the DACC-coated dressing or the control dressing.
  • Inability to give informed consent due to incapacity (as defined by the MCA 2005)
  • Aged under 18 years at the time of recruitment
  • Use of investigational drug/device therapy within preceding 4 weeks that may interfere with this study.

Treatment and study plan

DACC-Coated Post Operative Dressing

Device

Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.

Other names: Leukomed Sorbact

Primary outcomes

  1. 30 day infection rate

    Time frame: 30 days

    Surgical Site Infection at 30 days post-op

Secondary outcomes

  1. 3 month infection rate

    Time frame: 3 months

    Surgical Site Infection at 3 months post-op (implant patients only)

  2. Quality of Life (SF-36 V2)

    Time frame: 30 days, 3 months

    Score ranging from 0-100, higher values indicating better health

  3. Quality of Life (EQ-5D-3L)

    Time frame: 30 days, 3 months

    Score ranging from 5-15, higher scores indicating worse health

  4. Mortality

    Time frame: 30 days

    30-day mortality

  5. Bluebelle wound healing questionnaire

    Time frame: Days 30 and 37

    Score ranging 0-41, higher values indicating infection

  6. Carbon Footprint Analysis

    Time frame: 3 months

    Healthcare resource use data

Other outcomes

  1. SWAT 1 Validation Acceptability

    Time frame: 30 and 37 days

    Response rates to measure at 30 and 37 days

  2. SWAT 1 Validation reliability

    Time frame: 30 and 37 days

    Inter and intra rater reliability

  3. SWAT 1 Validation Validity

    Time frame: 30 days

    Sensitivity, specificity, ROC analysis, AUC

  4. SWAT 2 Hair Removal Feasibility

    Time frame: 30 days

    Safety/adverse events

  5. Carbon Footprint Model Development

    Time frame: 3 months

    Healthcare resource use data, consumable item weights

Sponsors and collaborators

Lead sponsor

Hull University Teaching Hospitals NHS Trust

Other Gov

Collaborators

  • University of Hull

Registry information

Official study title

A Randomised Controlled Trial to Assess the Clinical and Cost Effectiveness of Dialkylcarbamoylchloride (DACC) Coated Post-operative Dressings Versus Standard Care in the Prevention of Surgical Site Infection in Clean or Clean-contaminated, Vascular Surgery.

Acronym: DRESSINg

Important dates

Study start
2017
Primary completion
2025
Study completion
2025
First posted
Dec 14, 2016
Registry last updated
Jan 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.